A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
This company provides enabling technology to drug developers in order to create longer lasting slow release versions of their drugs. Amylin Pharma has a phase III drug candidate that uses their technology. This drug, Bydureon is aimed at helping people suffering from diabetes. The drug was recently reviewed by the FDA, which asked for more information but did not require additional trials. The drug is due for another FDA review by Oct 22. Alkermes stands to receive royalties once this drug is approved and should benefit greatly as the potential market for Bydureon is very large.